Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gary R Cutter

Showing results (31-40 of 296) with videos related to

Pageof 30
Sort By:
BMC Neurology|September 19, 2016
Laquinimod efficacy in relapsing-remitting multiple sclerosis: how to understand why and if studies disagreeGary R Cutter, Volker Knappertz, Nissim Sasson, et al.
Current Alzheimer Research|September 12, 2012
Biomarker positive and negative subjects in the ADNI cohort: clinical characterizationRichard E Kennedy, Lon S Schneider, Gary R Cutter, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|September 4, 2010
Requiring an amyloid-beta1-42 biomarker for prodromal Alzheimer's disease or mild cognitive impairment does not lead to more efficient clinical trialsLon S Schneider, Richard E Kennedy, Gary R Cutter, et al.
Multiple Sclerosis and Related Disorders|March 20, 2022
Do physical activity, cardiorespiratory fitness, and subcortical brain structures explain reduced walking performance in older adults with multiple sclerosis?Jessica F Baird, Gary R Cutter, Robert W Motl
Contemporary Clinical Trials|September 27, 2015
Two-group time-to-event continual reassessment method using likelihood estimationAmber Salter, John O'Quigley, Gary R Cutter, et al.
Alzheimer'S & Dementia (New York, N. Y.)|June 2, 2018
Effect of sample size re-estimation in adaptive clinical trials for Alzheimer's disease and mild cognitive impairmentGuoqiao Wang, Richard E Kennedy, Gary R Cutter, et al.
Journal of Alzheimer'S Disease : JAD|February 3, 2016
Post Hoc Analyses of ApoE Genotype-Defined Subgroups in Clinical TrialsRichard E Kennedy, Gary R Cutter, Guoqiao Wang, et al.
Medical Science Monitor : International Medical Journal of Experimental and Clinical Research|February 5, 2017
Continuous Electroencephalography (cEEG) Monitoring and Outcomes of Critically Ill PatientsAyaz M Khawaja, Guoqiao Wang, Gary R Cutter, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 25, 2013
The magnetic resonance imaging 'rule of five': predicting the occurrence of relapseCharity J Morgan, Ashutosh Ranjan, Inmaculada B Aban, et al.
Alzheimer'S & Dementia (New York, N. Y.)|October 4, 2016
Using baseline cognitive severity for enriching Alzheimer's disease clinical trials: How does Mini-Mental State Examination predict rate of change?Richard E Kennedy, Gary R Cutter, Guoqiao Wang, et al.
Pageof 30

Showing results (31-40 of 296) with videos related to

Sort By:
Pageof 30
BMC Neurology|September 19, 2016
Laquinimod efficacy in relapsing-remitting multiple sclerosis: how to understand why and if studies disagreeGary R Cutter, Volker Knappertz, Nissim Sasson, et al.
Current Alzheimer Research|September 12, 2012
Biomarker positive and negative subjects in the ADNI cohort: clinical characterizationRichard E Kennedy, Lon S Schneider, Gary R Cutter, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|September 4, 2010
Requiring an amyloid-beta1-42 biomarker for prodromal Alzheimer's disease or mild cognitive impairment does not lead to more efficient clinical trialsLon S Schneider, Richard E Kennedy, Gary R Cutter, et al.
Multiple Sclerosis and Related Disorders|March 20, 2022
Do physical activity, cardiorespiratory fitness, and subcortical brain structures explain reduced walking performance in older adults with multiple sclerosis?Jessica F Baird, Gary R Cutter, Robert W Motl
Contemporary Clinical Trials|September 27, 2015
Two-group time-to-event continual reassessment method using likelihood estimationAmber Salter, John O'Quigley, Gary R Cutter, et al.
Alzheimer'S & Dementia (New York, N. Y.)|June 2, 2018
Effect of sample size re-estimation in adaptive clinical trials for Alzheimer's disease and mild cognitive impairmentGuoqiao Wang, Richard E Kennedy, Gary R Cutter, et al.
Journal of Alzheimer'S Disease : JAD|February 3, 2016
Post Hoc Analyses of ApoE Genotype-Defined Subgroups in Clinical TrialsRichard E Kennedy, Gary R Cutter, Guoqiao Wang, et al.
Medical Science Monitor : International Medical Journal of Experimental and Clinical Research|February 5, 2017
Continuous Electroencephalography (cEEG) Monitoring and Outcomes of Critically Ill PatientsAyaz M Khawaja, Guoqiao Wang, Gary R Cutter, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|April 25, 2013
The magnetic resonance imaging 'rule of five': predicting the occurrence of relapseCharity J Morgan, Ashutosh Ranjan, Inmaculada B Aban, et al.
Alzheimer'S & Dementia (New York, N. Y.)|October 4, 2016
Using baseline cognitive severity for enriching Alzheimer's disease clinical trials: How does Mini-Mental State Examination predict rate of change?Richard E Kennedy, Gary R Cutter, Guoqiao Wang, et al.
Pageof 30